GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
11 11 2019
Historique:
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 27 10 2020
Statut: epublish

Résumé

To externally validate the accuracy of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) model against existing risk scores for stroke and major bleeding risk in patients with non-valvular AF in a population-based cohort. Retrospective cohort study. Danish nationwide registries. 90 693 patients with newly diagnosed non-valvular AF were included between 2010 and 2016, with follow-up censored at 1 year. External validation was performed using discrimination and calibration plots. C-statistics were compared with CHA Of the 90 693 included, 51 180 patients received oral anticoagulants (OAC). Overall median age (Q1, Q3) were 75 (66-83) years and 48 486 (53.5%) were male. At 1-year follow-up, a total of 2094 (2.3%) strokes/SE, 2642 (2.9%) major bleedings and 10 915 (12.0%) deaths occurred. The GARFIELD-AF model was well calibrated with the predicted risk for stroke/SE and major bleeding. The discriminatory value of GARFIELD-AF risk model was superior to CHA In a nationwide Danish cohort with non-valvular AF, the GARFIELD-AF model adequately predicted the risk of ischaemic stroke/SE and major bleeding. Our external validation confirms that the GARFIELD-AF model was superior to CHA

Identifiants

pubmed: 31719095
pii: bmjopen-2019-033283
doi: 10.1136/bmjopen-2019-033283
pmc: PMC6858250
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e033283

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: KF has received research grants Bayer/Janssen and AstraZeneca and Consulting/Fees Bayer, Sanofi/Regeneron and Verseon. FV has received honoraria for consulting and presentations from Bayer HealthCare, Boehringer Ibgelheimy, BMSPfizer and Daiichi-Sankyo. GHG has ownership of stocks in Novo Nordisk Pharmaceuticals and reports research grants from Pfizer, Bristol Myers Squibb, Boehringer Ingelheim and Bayer. CTP declares grants for studies from Bayer. Other authors have no conflicts of interest to declare.

Références

Circulation. 2019 Feb 5;139(6):775-786
pubmed: 30586754
Int J Cardiol. 2015;187:525-6
pubmed: 25846665
BMJ Open. 2017 Dec 21;7(12):e017157
pubmed: 29273652
Am Heart J. 2013 Jan;165(1):93-101.e1
pubmed: 23237139
BMJ. 2016 Sep 06;354:i4482
pubmed: 27599725
Br J Gen Pract. 2017 Sep;67(662):e588-e597
pubmed: 28630059
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
Am Heart J. 2012 Jan;163(1):13-19.e1
pubmed: 22172431
Heart. 2013 Aug;99(16):1166-72
pubmed: 23393083
Am J Med. 2010 Jul;123(7):638-645.e4
pubmed: 20609686
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Eur Heart J. 2019 Jun 14;40(23):1880-1887
pubmed: 29955849
BMJ Open. 2018 Jan 13;8(1):e018905
pubmed: 29331969
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
BMJ Open. 2015 Dec 09;5(12):e009267
pubmed: 26656021
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Am J Cardiol. 2017 Nov 1;120(9):1549-1556
pubmed: 28844514
Am J Med. 2015 Dec;128(12):1306-13.e1
pubmed: 26239094
Thromb Haemost. 2012 Jun;107(6):1053-65
pubmed: 22398417
J Am Coll Cardiol. 2015 Jan 27;65(3):225-32
pubmed: 25614418
Am Heart J. 2018 Jul;201:149-157
pubmed: 29807323
BMJ. 2011 Jan 31;342:d124
pubmed: 21282258
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Clin Cardiol. 2014 May;37(5):277-84
pubmed: 24652779
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Europace. 2015 Dec;17(12):1777-86
pubmed: 26321406
Circulation. 2004 Aug 31;110(9):1042-6
pubmed: 15313941
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
J Am Heart Assoc. 2018 Sep 18;7(18):e009766
pubmed: 30371183

Auteurs

Frederik Dalgaard (F)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark fdalgaard87@gmail.com.
Duke Clinical Research Institute, Duke University, Durham, United States.

Karen Pieper (K)

Duke Clinical Research Institute, Duke University, Durham, United States.
Department of Clinical Research, Thrombosis Research Institute, London, UK.

Freek Verheugt (F)

Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord-Holland, the Netherlands.

A John Camm (AJ)

Department of Cardiology, University of London St George's Molecular and Clinical Sciences Research Institute, London, UK.

Keith Aa Fox (KA)

Cardiology, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK.

Ajay K Kakkar (AK)

Department of Clinical Research, Thrombosis Research Institute, London, UK.
Department of Surgery, University College London, London, United Kingdom.

Jannik L Pallisgaard (JL)

Department of Cardiology, Bispebjerg Hospital, Kobenhavn, Denmark.

Peter V Rasmussen (PV)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark.

Henk van Weert (HV)

Department of General Practice, Amsterdam UMC, Amsterdam Public Health and Amsterdam Cardiovascular Sciences Research Institutes, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Tommi Bo Lindhardt (TB)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark.

Christian Torp-Pedersen (C)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark.
Department of Clinical Investigation and Cardiology, Nordsjællands Hospital, Hillerod, Denmark.

Gunnar H Gislason (GH)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark.
The Danish Heart Foundation, Copenhagen, Denmark.
The National Institute of Public Health, University of Southern Denmark, Odense, Denmark.

Martin H Ruwald (MH)

Cardiology, Gentofte Hospital, Hellerup, Copenhagen, Denmark.

Ralf E Harskamp (RE)

Department of General Practice, Amsterdam UMC, Amsterdam Public Health and Amsterdam Cardiovascular Sciences Research Institutes, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH